

Patient + Insurance Information

Patient Name: _____ DOB: _____ Sex: Male Female SSN: _____ Wt (kg/lbs): _____ Ht (cm/in): _____
 Address: _____ Phone: _____ Alternate: _____
 Caregiver Name: _____ Relation to Patient: _____ Phone: _____
 Insurance Plan: _____ Plan ID: _____ BIN #: _____ PCN #: _____ GRP #: _____

Please fax a copy of the front and back of the insurance card(s).

Prescriber + Shipping Information

Prescriber Name: _____ DEA: _____ NPI: _____
 Address: _____
 Phone: _____ Alternate: _____ Fax: _____ Email: _____
 If shipping to prescriber: First Fill Always Never

Clinical Information (Please fax all pertinent clinical and lab information)

Diagnosis Code: _____ D66 (Type A – Factor VIII Deficiency) D67 (Type B – Factor IX Deficiency) D68.0 (Von Willebrand Disease – Check Type: 1 2 3)
 Date of Diagnosis: _____ D68.1 (Type C – Factor XI Deficiency) D68.2 (Hereditary deficiency of other clotting factors) D68.311 (Acquired Hemophilia)
 D68.32 (Hemorrhagic disorder due to extrinsic circulating anticoagulants) Other: _____
 Circulating Factor _____ % Target Joints: No Yes _____ Access: Peripheral Butterfly PICC Implant Port Broviac® / Hickman®
 Severity: Severe (<1%) Moderate (1 - 5%) Mild (>5%) Protocol: Pre-Surgical Prophylaxis Immune Tolerance On-demand
 Inhibitor Activity: None Historical Current _____ BU/mL Start Date: _____ End Date: _____
 Comorbidities: _____
 Concomitant Medications: _____
 Allergies: NKDA Other: _____
 Current Patient Need: STAT/Urgent bleed Ongoing care or Not urgent Procedure scheduled for: _____

Prescription

Therapy Regimen for Factor or Inhibitor Products	<input type="checkbox"/> Prophylaxis _____/week	<input type="checkbox"/> Breakthrough bleed: As Needed	<input type="checkbox"/> Immune Tolerance: Frequency _____
	<input type="checkbox"/> Target Dose: _____ IU/kg <input type="checkbox"/> Dose: _____ IU ± _____ % (Assay variation) # Doses: _____ Refills: _____	<input type="checkbox"/> Minor: _____ ± _____ % <input type="checkbox"/> Moderate: _____ ± _____ % <input type="checkbox"/> Major: _____ ± _____ % # Doses: _____ Refills: _____	<input type="checkbox"/> Target Dose: _____ IU/kg <input type="checkbox"/> Dose: _____ IU ± _____ % (Assay variation) # Doses: _____ Refills: _____
Factor VIII (Recombinant)	<input type="checkbox"/> Advate® <input type="checkbox"/> Adynovate® <input type="checkbox"/> Afstyla® <input type="checkbox"/> Eloctate™ <input type="checkbox"/> Jivi® <input type="checkbox"/> Kogenate® FS <input type="checkbox"/> Kovaltry® <input type="checkbox"/> NovoEight® <input type="checkbox"/> Nuwiiq® <input type="checkbox"/> Recombinate® <input type="checkbox"/> Xyntha® <input type="checkbox"/> Xyntha® Solofuse		
Factor VIII (Human)	<input type="checkbox"/> Hemofil® M		
Factor VIII (Human) + VWF	<input type="checkbox"/> Alphanate® SD <input type="checkbox"/> Humate-P® <input type="checkbox"/> Koâte® DVI <input type="checkbox"/> Wilate®		
Factor IX (Recombinant)	<input type="checkbox"/> Alprolix® <input type="checkbox"/> Benefix® RT <input type="checkbox"/> Idelvion® <input type="checkbox"/> Ixinity® <input type="checkbox"/> Rebinyn® <input type="checkbox"/> Rixubis®		
Factor IX (Human)	<input type="checkbox"/> AlphaNine® SD <input type="checkbox"/> Mononine®		
Factor X (Human)	<input type="checkbox"/> Coagadex®		
Factor XIII (Human)	<input type="checkbox"/> Corifact®		
Anti-Inhibitor (Human)	<input type="checkbox"/> Feiba®		
Anti-Thrombin III (Human)	<input type="checkbox"/> Thrombate III®		
Protein C Concentrate (Recombinant)	<input type="checkbox"/> Ceprotin® <input type="checkbox"/> Acute episode/short-term prophylaxis <input type="checkbox"/> 500 IU <input type="checkbox"/> Quantity: <input checked="" type="checkbox"/> 1 month <input type="checkbox"/> Initial dose: 100-120 IU/kg IV <input type="checkbox"/> 1000 IU <input type="checkbox"/> Other: _____ <input type="checkbox"/> Subsequent 3 doses: 60-80 IU/kg IV every 6 hours <input type="checkbox"/> Maintenance dose: 45-60 IU/kg IV every 6 or 12 hours Refills: <input type="checkbox"/> 1 year or as otherwise specified <input type="checkbox"/> Long-term prophylaxis: Maintenance dose: 45-60 IU/kg every 12 hours <input type="checkbox"/> Other: _____		
Pro-Thrombin Complex (Human)	<input type="checkbox"/> Bebulin® VH <input type="checkbox"/> Profilnine® SD		
Von Willebrand Factor (Recombinant)	<input type="checkbox"/> Vonvendit®		
Acquired Hemophilia A	<input type="checkbox"/> Obizur®		
Gene therapy	<input type="checkbox"/> Roctavian® (Hemophilia A) <input type="checkbox"/> Hemgenix® (Hemophilia B)		
Factor XIII-A subunit (Recombinant)	<input type="checkbox"/> Tretten® 35 IU/kg SQ once monthly <input checked="" type="checkbox"/> Quantity: <input checked="" type="checkbox"/> 1 month <input type="checkbox"/> Other: _____ Refills: <input type="checkbox"/> 1 year or as otherwise specified <input type="checkbox"/> Other: _____		

Medication	Strength	Dose & Direction	Quantity/Refills
<input type="checkbox"/> Altuvio Factor VIII (Recombinant)	<input type="checkbox"/> 50 IU/kg <input type="checkbox"/> ____ IU/kg	<input type="checkbox"/> Prophylaxis: 50 IU/kg IV once weekly <input type="checkbox"/> On demand treatment: 50 IU/kg IV as needed for bleeding episodes. Contact your physician's office if bleeding does not resolve. <input type="checkbox"/> Other: _____ Weight: ____ kg	Quantity: <input checked="" type="checkbox"/> 1 month <input type="checkbox"/> Other: _____ Refills: <input type="checkbox"/> 1 year or as otherwise specified <input type="checkbox"/> Other: _____
<input type="checkbox"/> Esperoct Factor VIII (Recombinant)	<input type="checkbox"/> ____ IU /kg	<input type="checkbox"/> Prophylaxis: ____ IU/kg IV every ____ days or ____ times per week <input type="checkbox"/> On demand treatment: ____ IU/kg IV as needed for bleeding episodes. Contact your physician's office if bleeding does not resolve. <input type="checkbox"/> On demand treatment: ____ IU/kg IV as needed for bleeding episodes. Contact your physician's office if bleeding does not resolve.	Quantity: <input checked="" type="checkbox"/> 1 month Refills: <input type="checkbox"/> 1 year or as otherwise specified <input type="checkbox"/> Other: _____
<input type="checkbox"/> Hemlibra	<input type="checkbox"/> 30 mg/mL <input type="checkbox"/> 60 mg/0.4 mL <input type="checkbox"/> 105 mg/0.7 mL <input type="checkbox"/> 150 mg/1 mL <input type="checkbox"/> 300mg/2 ml <input type="checkbox"/> 12 mg/0.4mL	<input type="checkbox"/> Initial dose: 3 mg/kg subcutaneously once weekly for 4 weeks <input type="checkbox"/> Maintenance dose: <input type="checkbox"/> 1.5 mg/kg subcutaneously every week <input type="checkbox"/> 3 mg/kg subcutaneously every 2 weeks <input type="checkbox"/> 6 mg/kg subcutaneously every 4 weeks Weight: ____ kg	Quantity: <input checked="" type="checkbox"/> 1 month <input type="checkbox"/> Other: _____ Refills: <input type="checkbox"/> 1 year or as otherwise specified <input type="checkbox"/> Other: _____
<input type="checkbox"/> NovoSeven RT Factor VIIa (Recombinant)	<input type="checkbox"/> ____ mcg/kg	Infuse ____ mcg/kg slow IV push every ____ hours, and/or _____ _____ Weight: ____ kg	Quantity: <input checked="" type="checkbox"/> 1 month <input type="checkbox"/> Other: _____ Refills: <input type="checkbox"/> 1 year or as otherwise specified <input type="checkbox"/> Other: _____
<input type="checkbox"/> SevenFact Anti-Inhibitor (Recombinant)	<input type="checkbox"/> 1 mg <input type="checkbox"/> 5 mg	For Mild/Moderate bleeds: <input type="checkbox"/> 75 mcg/kg IV, repeat q 3 hours until hemostasis achieved or <input type="checkbox"/> Initial dose of 225 mcg/kg IV. May infuse 75 mcg/kg IV q 3 hours prn if hemostasis not achieved within 9 hours. For Severe bleeds: <input type="checkbox"/> 225 mcg/kg IV, followed if necessary 6 hours later with 75 mcg/kg IV every 2 hours. <input type="checkbox"/> Other _____ Round to nearest whole vial. Weight: ____ kg	Quantity: <input checked="" type="checkbox"/> 1 month <input type="checkbox"/> Other: _____ Refills: <input type="checkbox"/> 1 year or as otherwise specified <input type="checkbox"/> Other: _____
Flushing Protocol	<input type="checkbox"/> Sodium Chloride 0.9% 5-10 mL pre and post medications		<input type="checkbox"/> Heparin _____ units/mL _____ mL as needed
Ancillary Supplies	<input checked="" type="checkbox"/> Dispense infusion supplies as needed for proper administration and disposal.		
Skilled Nursing Visits	<input checked="" type="checkbox"/> All nursing services requirements to be completed per pharmacy protocol including teaching as needed.		
Other Medications	<input type="checkbox"/> Amicar®	<input type="checkbox"/> Tablet <input type="checkbox"/> Syrup	Directions: _____ Qty: _____ Refills: _____
	<input type="checkbox"/> Lysteda®		Directions: _____ Qty: _____ Refills: _____
	<input type="checkbox"/> Stimate®	<input type="checkbox"/> 150mcg <input type="checkbox"/> Wt < 50kg <input type="checkbox"/> 300mcg <input type="checkbox"/> Wt > 50kg	Single spray in one nostril Single spray in both nostrils Qty: _____ Refills: _____ Qty: _____ Refills: _____
	<input type="checkbox"/> Anaphylaxis Order	<input type="checkbox"/> Epinephrine Pen 0.3mg (> 30kg) <input type="checkbox"/> Epinephrine Pen 0.15mg (15-30kg)	Directions: Use as directed for Anaphylaxis; may repeat in 5-10 minutes x 1 Qty: 2 Refills: _____
Prescriber's Signature: _____ Date: _____ I authorize AmeriPharma and its representatives to act as an agent to initiate and execute the insurance prior authorization process for this prescription and any future fills of the same prescription for the patient listed above. I understand that I can revoke this designation at any time by providing written notice to AmeriPharma.			